Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cellnon-Hodgkin’s lymphoma: a single institution study
Authors:
- K. BelhadjKBK. Belhadj
- M.-H. Delfau-LarueMDM.-H. Delfau-Larue
- J.-L. BeaumontJBJ.-L. Beaumont
- J.-P. FarcetJFJ.-P. Farcet
Open Access
- 1 March 2004
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 15 (3) , 504-510
Abstract
Background: Rituximab induces clinical response in advanced B-cell lymphoma and is efficient in removing circulating B-cell from peripheral blood. We therefore postulated that rituximab might be a useful in vivo purging agent before high-dose therapy in this setting. Patients and methods: Fourteen patients with relapsed follicular, marginal zone and mantle cell lymphomas (11, two and one cases, respectively) and a PCR-detectable molecular marker were treated first with rituximab, then a mobilization chemotherapeutic regimen, followed by high-dose therapy with peripheral blood stem cell transplantation. PCR analyses were performed in peripheral blood before rituximab and during follow-up, and in harvest. Results: Harvests were free of PCR-detectable molecular marker in nine of the 11 studied cases (82%). After high-dose therapy, clinical complete remission was obtained in 13 (93%) patients and molecular remission in 11 (79%). With a median follow-up of 3 years, the 14 transplanted patients were alive, 11 of them remaining in clinical complete remission and eight in molecular remission at last follow-up. Conclusion: Rituximab treatment followed by high dose therapy appears to be effective in achieving complete clinical and molecular response. In vivo harvest purging is predictive of prolonged clinical and molecular remission.Keywords
This publication has 34 references indexed in Scilit:
- Survival Benefit of High-Dose Therapy in Poor-Risk Aggressive Non-Hodgkin’s Lymphoma: Final Analysis of the Prospective LNH87–2 Protocol—A Groupe d’Etude des Lymphomes de l’Adulte StudyJournal of Clinical Oncology, 2000
- Long-Term Follow-Up of Autologous Bone Marrow Transplantation in Patients With Relapsed Follicular LymphomaBlood, 1999
- Immunomagnetic bone marrow (BM) and peripheral blood progenitor cell (PBPC) purging in follicular lymphoma (FL)Bone Marrow Transplantation, 1999
- Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma.Journal of Clinical Oncology, 1998
- VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.Journal of Clinical Oncology, 1998
- Autologous stem-cell transplantation for non-Hodgkin's lymphomas: the role of graft purging and radiotherapy posttransplantation--results of a retrospective analysis on 120 patients autografted in a single institution.Journal of Clinical Oncology, 1998
- Purging Peripheral Blood Progenitor Cell Grafts from Lymphoma Cells: Quantitative Comparison of Immunomagnetic CD34 + Selection SystemsStem Cells, 1997
- High-Dose Chemotherapy and Autologous Bone Marrow Transplantation Compared with MACOP-B in Aggressive B-Cell LymphomaNew England Journal of Medicine, 1997
- High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma.Journal of Clinical Oncology, 1997
- Comparative Preclinical Study of Three Bone Marrow Purging Methods Using PCR Evaluation of Residual t(14;18) Lymphoma CellsLeukemia & Lymphoma, 1996